About Event

Why Attend the 7th Obesity & NASH Drug Development Summit?

Your one-stop shop to capturing industry’s most exciting developments in tackling metabolic syndromes 

The fluctuating obesity and NASH landscape and failures has herded many former players away, but leading biopharma are determined to thrive in this ever-growing market.

With the obesity market expected to grow to $50 billion by 2030, the 7th Obesity & NASH Drug Development Summit is your timely meeting, uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs, tri-agonists, dual agonists, tetra-specific drugs, glucocorticoid receptor modulators and more!

The evolution in digital pathology, artificial intelligence, omics, multifunctional molecules, non-invasive biomarkers, target discovery and liver models are deeming 2023 an exciting year to bring the metabolic community closer to even more approvals.

Don’t miss your opportunity to hear from 12 new speaker companies and 34 new speakers over 3 days jam-packed with all the latest end-to-end focal updates!

Unmissable highlights for 2023:


Turbocharge the development of NASH treatments with insights from Madrigal’s Resmetirom to reduce liver fat and its potential to become the first NASH medication on the market


Discover the full potential spatial transcriptomic technologies, analytical tools and human genetics hold with Eli Lilly, Regeneron and OliX pharmaceuticals to better understand obesity pathogenesis and derive robust targets


Accelerate the GLP-1 revolution with Novo Nordisk by targeting GLP-1, GIP and glucagon receptors and advance the future of oral incretins


Better inform clinical study design with Hepion Pharmaceuticals, Cirius Therapeutics and Pfizer by leveraging the power of artificial intelligence to aide the selection of appropriate subjects and standardize the evaluation of NASH features


Move away from 2D models and explore the use of 3D human cell-based liver models with Viscient Bio to accurately predict clinical success and failure 

Who Will You Meet?

MicrosoftTeams-image (44)
MicrosoftTeams-image (45)

What Your Peers Have to Say:


"The quality of the presenters was excellent"

aria pharma logo

“Excellent speakers, good topics on agenda and networking opportunity to meet likeminded group”


“Ample opportunities to make personal connections and discuss findings and new perspectives in person with fellow conference goers”

corcept therapeutix

"Attending this meeting provides an important opportunity to network with leading researchers and colleagues in Industry and keep up with cutting edge research and developments in NASH"